475830.KQ
Orum Therapeutics, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 54,500.00
−3.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 24.1M | 23.6M | 14.1M | 104.6M | 60.3K |
| Cost of Revenue | 7.0B | 257.0K | 1.3K | — | 656.53 |
| Gross Profit | (1.6B) | 23.3M | 14.1M | 104.6M | 59.7K |
| Operating Expenses | |||||
| R&D Expense | 10.8B | 24.6M | 11.5M | 14.5M | 26.4M |
| SG&A Expense | 9.9B | 5.9B | 3.9B | 13.1B | 4.8B |
| General & Admin Expense | 1.6B | 2.4B | 833.3M | 771.0M | 835.1M |
| Selling & Marketing Expense | 2.7B | 3.5B | 3.1B | 12.3B | 4.0B |
| Other Expenses | 11.2B | 36.0B | (3.9B) | (13.1B) | (4.8B) |
| Total Operating Expenses | 31.8B | 41.9B | 17.6M | 29.2M | 33.6M |
| Cost and Expenses | 33.5B | 51.8B | 17.6M | 29.2M | 33.6M |
| Operating Income (EBIT) | (33.5B) | (51.8B) | (3.6M) | 95.6B | (33.5M) |
| Non-Operating | |||||
| Interest Income | 2.3B | 1.1B | 2.1M | 560.8M | 671.0M |
| Interest Expense | 1.9B | 1.9B | 1.2M | 824.4M | 75.4M |
| Net Interest Income | 423.8M | (752.4M) | 932.1K | (263.5M) | 595.6M |
| Other Non-Op Income/Expense | 82.0B | 7.6B | 3.0B | (27.7B) | (16.6M) |
| Non-Operating Income (excl Interest) | (3.3B) | — | 2.0M | 26.9B | 1.2M |
| EBT (Pre-Tax Income) | 29.9B | (44.2B) | (3.6M) | 67.9B | (50.1M) |
| Income Tax Expense | 2.2B | 2.2B | 286.0K | 319.0M | 179.1K |
| Bottom Line | |||||
| Net Income | 48.1B | (42.0B) | (3.9M) | 52.7M | (50.3M) |
| Earnings from Cont. Ops | 48.1B | (42.0B) | (3.9M) | 68.2B | (50.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 48.1B | (42.0B) | (3.9M) | 52.7M | (50.3M) |
| Per Share | |||||
| Basic EPS | ₩2,260 | (₩2,017) | (₩0) | ₩14,830 | (₩13,765) |
| Diluted EPS | ₩2,260 | (₩2,017) | (₩0) | ₩5,646 | (₩13,765) |
| Revenue Per Share | ₩1 | ₩1 | ₩1 | ₩23 | ₩0 |
| Shares | |||||
| Basic Shares Outstanding | 21.6M | 20.8M | 13.5M | 4.6M | 4.6M |
| Diluted Shares Outstanding | 21.6M | 20.8M | 13.5M | 12.1M | 4.6M |
| Profitability Metrics | |||||
| EBITDA | (28.5B) | (48.5B) | (3.7M) | 75.2M | (33.7M) |
| D&A | 1.7B | 3.3B | 1.9M | 1.4M | 1.0M |
| EBIT | (30.2B) | (51.8B) | (5.6M) | 73.9M | (34.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026